What question did this study set out to answer?

To characterize the temporal dynamics of the microbiome, metabolites, and gut barrier integrity across varying severity stages in hospitalized COVID-19 patients.

August 15, 2026Gut Microbes ReportsOpen Access

Longitudinal multi-omic dynamics in hospitalized COVID-19 patients based on disease severity

View Full Paper

Ask AI

Bookmark

Authors

CBChristopher M. Basting TSTy Schroeder RSR. Shields-Cutler

Discussion

Member takes

Overview

Longitudinal study reveals gut barrier breakdown, pathogen expansion, and metabolite loss in severe COVID-19 patients, highlighting the need for early microbiome-targeted interventions.

Key Points

To characterize the temporal dynamics of the microbiome, metabolites, and gut barrier integrity across varying severity stages in hospitalized COVID-19 patients.
Longitudinal study of 22 hospitalized COVID-19 patients classified as moderate, severe, or critical by WHO criteria in Milan, Italy.
Measured rectal and nasal microbiomes, plasma cytokines, bile acids, fatty acids, and gut barrier damage markers across up to three timepoints over an average of 9 days.
Critically ill patients showed sustained elevations in pro-inflammatory cytokines (IL-6, IL-8, TNFα) alongside increased gut barrier damage markers (LBP, zonulin, sCD14).
Severe disease was associated with early depletion of beneficial commensals like Faecalibacterium prausnitzii, bloom of opportunistic pathogens (Hungatella hathewayi, Erysipelatoclostridium ramosum), and progressive loss of secondary and conjugated bile acids.
Commensal bacteria correlated with reduced gut barrier damage, whereas opportunistic pathogens positively correlated with elevated IL-6 levels.

Cite This Study

Basting et al. (2026) studied this question.

synapsesocial.com/papers/6a8019ce75c2e31742c85fe1 https://doi.org/10.1080/29933935.2026.2712728

View Full Paper

Ask AI

Bookmark

August 15, 2026Gut Microbes ReportsOpen Access

Longitudinal multi-omic dynamics in hospitalized COVID-19 patients based on disease severity

View Full Paper

Ask AI

Bookmark

Authors

CBChristopher M. Basting TSTy Schroeder RSR. Shields-Cutler

Discussion

Member takes

Overview

Longitudinal study reveals gut barrier breakdown, pathogen expansion, and metabolite loss in severe COVID-19 patients, highlighting the need for early microbiome-targeted interventions.

Key Points

To characterize the temporal dynamics of the microbiome, metabolites, and gut barrier integrity across varying severity stages in hospitalized COVID-19 patients.
Longitudinal study of 22 hospitalized COVID-19 patients classified as moderate, severe, or critical by WHO criteria in Milan, Italy.
Measured rectal and nasal microbiomes, plasma cytokines, bile acids, fatty acids, and gut barrier damage markers across up to three timepoints over an average of 9 days.
Critically ill patients showed sustained elevations in pro-inflammatory cytokines (IL-6, IL-8, TNFα) alongside increased gut barrier damage markers (LBP, zonulin, sCD14).
Severe disease was associated with early depletion of beneficial commensals like Faecalibacterium prausnitzii, bloom of opportunistic pathogens (Hungatella hathewayi, Erysipelatoclostridium ramosum), and progressive loss of secondary and conjugated bile acids.
Commensal bacteria correlated with reduced gut barrier damage, whereas opportunistic pathogens positively correlated with elevated IL-6 levels.

Cite This Study

Basting et al. (2026) studied this question.

synapsesocial.com/papers/6a8019ce75c2e31742c85fe1 https://doi.org/10.1080/29933935.2026.2712728

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark